All In Biotech

Free tool

FAERS Monitor: Gonal-F

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 021765 or its brand name (Gonal-F, Follitropin Alfa/Beta). Reports on generic versions are filed under their own applications.

Reports

2,046

Serious

1,696

83% of reports

Hospitalization

983

Death reported

32

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ovarian hyperstimulation syndrome696
  • ascites223
  • abdominal pain130
  • abortion spontaneous123
  • abdominal distension120
  • nausea104
  • dyspnoea100
  • vomiting85
  • inappropriate schedule of drug administration80
  • drug ineffective78
  • pleural effusion76
  • off label use75
  • drug exposure during pregnancy58
  • maternal exposure during pregnancy54
  • headache53

Reports by year received

View as table
YearReports
200415
200521
200618
200745
200843
200944
201054
201165
201279
2013109
2014139
2015114
2016102
2017174
2018110
2019165
2020116
202145
2022127
2023143
2024129
2025100
202689

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,113 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ovarian hyperstimulation syndromeSignal6964374.74049.02,132,647
ascitesSignal22378.669.416,894
abortion spontaneousSignal12331.726.73,616
drug exposure during pregnancySignal5817.613.6889
pleural effusionSignal7612.910.3820
abdominal distensionSignal12011.89.91,183
inappropriate schedule of drug administrationSignal8011.69.3764
maternal exposure during pregnancySignal546.24.8233
abdominal painSignal1305.74.9510
vomiting851.91.534
dyspnoea1001.81.537
nausea1041.41.19
off label use750.90.71
headache530.90.71
drug ineffective780.60.521

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.